All News
-
ASM Microbe 2018: Nosopharm to present new first-inclass clinical candidate to tackle interobacteriaceae infections
Read MoreNOSO-502 is on track to be the first novel antibiotic class for the Enterobacteriaceae infections to be introduced into the clinics for 40 years. First-In-Human (FIH) studies are expected to start in 2020
-
Nosopharm renews its partnership with Inra
Read MoreThis second screening campaign aims to discover new classes ofantimicrobial agents for treating multi-resistant infections
-
MOTIF BIO REVIVE-2 PHASE 3 STUDY RESULTS WITH ICLAPRIM PUBLISHED IN PEER-REVIEWED JOURNAL, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Read MoreIclaprim met the primary endpointIclaprim was well tolerated in the study, with no nephrotoxicity observedAdditional data from the previously announced results are included in the publication
-
Antibiotic resistance: Nosopharm and the University of Illinois at Chicago describe mechanism of action of new class of antibiotics in Molecular Cell
Read MoreNewly discovered antibiotic binds to ribosome and disrupts protein synthesis
-
Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies
Read MoreTransaction provides potential for further development of novel mAbs while allowing Arsanis to continue to focus its resources on ongoing Phase 2 clinical trial of lead product candidate ASN100
-
Polyphor announces enrollment of first patient in Phase III clinical trial for murepavadin – a pathogen-specific antibiotic being developed for the treatment of nosocomial pneumonia
Read MorePotentially first new class of antibiotics in Phase III development against Gram-negative pathogens in 50 years